Most NAD+ marketing treats the gut as a delivery problem — something a capsule has to survive. A trial published in Nature Metabolism in January 2026 suggests the gut may be doing something closer to the opposite: actively converting oral NMN and nicotinamide riboside into a different molecule, which is then the thing that raises your NAD+. If that holds up, a lot of what people believe about how NAD+ precursors work is one step out of date. This piece covers what the new NAD+ research actually showed, where it's still thin, and what it means in Australia now that NMN sits inside the TGA's permitted-ingredient framework.

What is NAD+, and why the gut suddenly matters

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme — not a peptide, despite where it usually gets shelved in the "peptide" marketplace. It's central to energy metabolism and to enzymes like sirtuins and PARPs, and tissue levels appear to decline with age. Because NAD+ itself is a large, charged molecule that doesn't absorb well orally, the field has spent a decade on precursors: nicotinamide (Nam), nicotinamide riboside (NR), nicotinamide mononucleotide (NMN) and plain nicotinic acid (niacin).

The standard story is that NR and NMN get absorbed, enter cells, and get salvaged into NAD+. The emerging story adds a detour through your microbiome.

NAD+ research: what the 65-person comparison trial found

Researchers at the Nestlé Institute of Health Sciences ran a randomised, open-label, placebo-controlled, parallel-group study in 65 healthy adults, comparing NR (1,000 mg/day), NMN (1,000 mg/day), nicotinamide (500 mg/day) and placebo over 14 days. It was published in Nature Metabolism on 15 January 2026.

Two headline results:

  • NR and NMN both raised circulating NAD+ over 14 days, roughly doubling blood levels. Nicotinamide only produced an acute rise around four hours after dosing, without the same sustained effect.
  • The route appears to run through gut bacteria. In companion laboratory work, human gut bacteria exposed to NMN and NR converted both into nicotinic acid — and nicotinic acid, in the researchers' blood experiments, was a strikingly efficient NAD+ precursor in its own right.

The team also reported shifts in gut microbial metabolism, including higher short-chain fatty acid concentrations. That part is the most speculative: SCFAs are associated with gut barrier integrity and lower systemic inflammation, but this trial measured metabolites, not health outcomes.

This didn't come out of nowhere

The microbiome angle has preclinical precedent. Chellappa and colleagues, writing in Cell Metabolism in December 2022, traced NAD precursor flux in mice and concluded that dietary precursors are largely absorbed high in the gut, while circulating host nicotinamide leaks into the gut lumen, gets converted to nicotinic acid by microbes, and is returned to host tissues. Their blunt conclusion: the main route from oral nicotinamide riboside to host NAD is via microbial conversion to nicotinic acid. That work was in mice and germ-free mice — animal-only, and it should be read as mechanism, not proof in humans.

Where this evidence is genuinely thin

Three caveats worth stating plainly.

It's 14 days and a surrogate endpoint. Blood NAD+ is a biomarker, not a benefit. No clinical outcome — strength, fatigue, cognition, cardiometabolic markers — was the primary question here. Our earlier coverage on why blood NAD isn't brain NAD applies with full force.

It was open-label and industry-run. Nestlé Health Science is a commercial participant in the healthy-ageing supplement category. That doesn't invalidate the data, but open-label design plus sponsor interest is a reason to wait for independent replication rather than treat it as settled.

The microbiome-modulation claim has a contradicting human dataset. A 2023 paper in npj Aging reported that oral NR altered intestinal microbial composition in rats and mice — but not in humans. Its title says so explicitly. So "NAD+ boosters reshape your microbiome" is, at best, unresolved across human studies.

And the obvious question nobody has answered well. If microbe-made nicotinic acid does the heavy lifting, why not just take nicotinic acid? It's cheap and long-available. The practical answer has always been flushing at higher doses — well documented and often intolerable. Whether NMN and NR are best understood as slow, flush-free delivery systems for nicotinic acid is a genuinely interesting hypothesis, and it has not been tested head-to-head against niacin for clinical outcomes.

NAD+ Australia: is NMN legal in Australia, and does the dose match the trial?

This is where the research and the Australian rulebook diverge in a way worth noticing.

On 10 December 2025, the TGA added nicotinamide mononucleotide to the Permissible Ingredients Determination — making Australia the first country to bring NMN formally inside a therapeutic-goods framework. The conditions are specific:

  • Oral route only, as an active ingredient
  • Maximum recommended daily dose of 500 mg NMN
  • Sponsor exclusivity until 10 December 2027, restricted to SyncoZymes (Shanghai) Co Ltd as primary sponsor, or secondary sponsors it has authorised

Two consequences follow. First, the trial dosed 1,000 mg/day — double what a listed Australian medicine may recommend. Anyone reading the Nature Metabolism result and assuming an ARTG-listed Australian NMN product reproduces it is extrapolating across a two-fold dose gap.

Second, the rest of the family is treated differently. NR is a permitted ingredient. NAD+ and NADH are not, which is why NAD+ itself cannot lawfully be used as an ingredient in an Australian listed medicine, and why the TGA has published separate guidance on how NAD-related representations may be made. Intravenous NAD+ — heavily promoted through wellness clinics — remains a route with very little published clinical evidence behind it, regardless of how the oral precursor science evolves.

Internationally, the direction has been loosening: the FDA reversed its NMN exclusion in September 2025, reopening the US supplement pathway. Australia's approach is narrower and more conditional — a capped dose, a fixed route, and a named sponsor.

For more on the wider compound landscape, see our peptides index and the full NAD+ profile. If you'd like new research summaries as they land, join the free updates list.

FAQ

Does NMN work through the gut microbiome?

Partly, according to a January 2026 Nature Metabolism trial: human gut bacteria converted NMN and NR into nicotinic acid, an efficient NAD+ precursor. This is one trial plus mouse mechanism work, and a separate 2023 human study found NR did not alter human gut microbial composition.

Is NMN legal in Australia in 2026?

Yes, with conditions. Since 10 December 2025 NMN is a TGA permitted ingredient for oral listed medicines at a maximum recommended daily dose of 500 mg, with sponsor exclusivity to SyncoZymes until 10 December 2027. NAD+ and NADH remain non-permitted ingredients; NR is permitted.

Is nicotinic acid (niacin) a better NAD+ booster than NMN?

Unknown. The new lab work suggests nicotinic acid is a highly efficient NAD+ precursor, but no trial has compared niacin against NMN or NR on clinical outcomes in humans, and higher-dose niacin causes well-documented flushing.

How much NMN did the 2026 trial participants take?

NR and NMN were each dosed at 1,000 mg/day and nicotinamide at 500 mg/day, over 14 days in 65 healthy adults. That NMN dose is double the maximum daily dose permitted for Australian listed medicines.

Sources

This article is independent information, not medical advice. NAD+ is a coenzyme, not a peptide; NMN and NR are permitted ingredients in Australian listed medicines under specific conditions, while NAD+ and NADH are not, and intravenous NAD+ is not an approved therapy. retatrutide.net.au is not affiliated with any manufacturer or supplier.